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Abstract
Background: To investigate mechanisms that determine healthy aging is of major interest in the modern world
marked by longer life expectancies. In addition to lifestyle and environmental factors genetic factors also play an
important role in aging phenotypes. The aged immune system is characterized by a chronic micro-inflammation,
known as inflamm-aging, that is suspected to trigger the onset of age-related diseases such as cardiovascular
disease, Alzheimer’s disease, cancer, and Diabetes Mellitus Type 2 (DMT2). We have recently shown that a Toll-like
receptor 6 variant (P249S) is associated with susceptibility to cardiovascular disease and speculated that this variant
may also be associated with healthy aging in general by decreasing the process of inflamm-aging.
Results: Analyzing the PolSenior cohort we show here that nonsmoking S allele carriers are significantly
protected from age-related diseases (P = 0.008, OR: 0.654). This association depends not only on the association
with cardiovascular diseases (P = 0.018, OR: 0.483) for homozygous S allele carriers, but is also driven by a protection
from Diabetes Mellitus type 2 (P = 0.010, OR: 0.486) for S allele carriers. In addition we detect a trend but no significant
association of this allele with inflamm-aging in terms of baseline IL-6 levels.
Conclusion: We confirm our previous finding of the TLR-6 249S variant to be protective regarding cardiovascular
diseases. Furthermore, we present first evidence of TLR-6 249S being involved in DMT2 susceptibility and may be
in general associated with healthy aging possibly by reducing the process of inflamm-aging.
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Background
The process of successful aging and longevity is complex
and far from being understood. Lifestyle, environment,
and a limited aging-related impairment of the immune
system (termed immunosenescence) are among the most
important factors contributing to the healthy aging
phenotype. The aged adaptive immune system is char-
acterized by a decreased effectiveness due to decreased
T- and B-cell responses and accumulation of function-
ally impaired memory lymphocytes [1]. Furthermore,
the aged adaptive immune system is characterized by a
dysregulation of T-cell subtypes, with a relative increase
of Th2 lymphocytes resulting in increased levels of Th2
cytokines [2]. The aged innate immune system is charac-
terized by reduced functions of neutrophils, macrophages,
NK cells, and dendritic cells [3]. In addition, an important
feature of the aged immune system is a chronic low grade
inflammatory state, also known as micro-inflammation or
inflamm-aging, which has been suspected to trigger aging-
associated diseases such as cardiovascular disease (CVD),
diabetes mellitus type 2 (DMT 2), metabolic syndrome,
and neurodegeneration [4]. The mechanisms inducing the
process of inflamm-aging are multifactorial and not com-
pletely understood. One reason may be the dysregulation
of T lymphocyte subtypes. An enhanced translocation of
gut bacteria as well as an enhanced DNA-damage in the
elderly, which both trigger the innate pro-inflammatory
immune response, are also discussed [5–7]. Furthermore,
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epigenetic changes in innate immune cells are discussed
to be involved in inflamm-aging [8].
However, numerous genetic factors have also been pro-
posed to influence aging. Several studies show that healthy
aging and particularly longevity are highly heritable. For
example, siblings of centenarians also have an enhanced
probability for a longer healthy life [9, 10]. Genetic varia-
tions associated with the onset of age-related diseases such
as atherosclerosis resulting in CVD, DMT 2, Alzheimer’s
Disease, and cancer may play a pivotal role in determining
successful aging [11]. Among aging-associated diseases,
CVD plays a crucial role regarding mortality in the
middle-aged population of the Western world [12, 13]. Re-
cently, we have shown that the Toll-like receptor (TLR)-6
SNP P249S is associated with the risk for CVD with the
homozygous S/S variant protecting from CVD. We also
speculated whether this SNP may influence successful
aging in general [14].
It has been shown that aging is associated with the
dysregulation of expression and signal transduction of a
variety of innate immune receptors, among them TLRs
[15]. TLRs are important receptors of the innate immune
system recognizing “pathogen associated molecular pat-
terns (PAMPs)” followed by the activation of the innate
immune response [16]. Although the process of inflamma-
tion is fundamental for survival in terms of combating
infections or coping with damaging agents, it is also an
important cause of many aging-associated diseases such
as atherosclerosis, DMT 2, cognitive decline, and cancer,
since these diseases are all associated with chronic inflam-
mation [17]. The inflammatory response is driven by a
variety of signaling pathways, however, the transcription
factor NFκB has been considered to be the master regula-
tor of inflammation [18], and is also a central part of TLR
signaling [16].
Since inflamm-aging seems to be one of the reasons
for the development of aging-related diseases, we postu-
lated previously that variations within the TLR-system
that decrease the inflammatory response may lead to a
decreased process of inflamm-aging and may be, there-
fore, beneficial in terms of healthy aging. First evidence
for this hypothesis was given by the finding that such
variations are overrepresented in healthy elderly subjects
in comparison to healthy younger subjects [19]. Follow-
ing this discovery, we here investigated a cohort of eld-
erly Caucasians and show that in nonsmoking elderly
subjects the TLR-6 SNP P249S is associated with healthy
aging. Analysis of certain aging related diseases revealed
a significant protective effect on CVD and DMT 2.
Methods
Study subjects
A sub-group of 1544 participants of the PolSenior pro-
gram, the first ones for whom the complete medical
records (including, among others, data on cardio-vascular
and respiratory diseases, cancer, diabetes, stroke and cog-
nitive impairment) and DNA samples were available at
the beginning of current study, was analyzed. PolSenior
was a multicenter, interdisciplinary project, designed to
assess health and socio-economic status of the Polish
Caucasians aged ≥65 years. Details of the PolSenior re-
cruitment are described elsewhere [20]. Project partici-
pants completed a detailed questionnaire regarding their
medical, social, and economic past and current health
status, underwent an examination including elements of
comprehensive geriatric assessment, and donated blood
for biochemical and genetic analyses. Steady state IL-6
level were measured using ELISA method (R&D System,
Minneapolis, MN, USA, sensitivity 0.04 pg/mL). Blood
pressure was measured three times during the first and
second visit using validated, automatic blood pressure
measuring device (A&D UA 787, A&D Company Limited,
Tokyo, Japan) in a seated position. The study subject was
diagnosed as suffering from hypertension if his/her aver-
age blood pressure from these measurements was ≥ 140/
90 mmHg, or the disease has been previously diagnosed
and the patient was taking hypotensive drugs over the past
two weeks. The study was approved by the Bioethics
Commission of the Medical University of Silesia in
Katowice. All participants gave a written, informed con-
sent for participation in the study. All investigations were
carried out in accordance with the ethical guidelines
of the 1975 Declaration of Helsinki. Subjects with
MMSE < 24, determined according to the Polish version of
the Mini-Mental State Examination test, were classified as
subjects with cognitive impairment. According to Akbaraly
et al. we set IL-6 levels ≤1.0 ng/L as low, 1.1–2.0 ng/L as
intermediate, and >2 ng/L as high [21]. Low IL-6 levels
were used as reference in logistic regression analysis.
Genotyping
Genomic DNA was prepared by standard procedures
from whole blood. Genotyping for TLR-6 SNP P249S
(rs5743810) was performed by melting curve analysis
as described previously [14]. Melting curve analysis
was carried out employing primers gaaagactctgaccagg
cat (forward), ctagtttattcgctatccaagtg (reverse), and
FRET-hybridization probes: accagaggtccaaccttactgaa-
FL and LC-red 640-ttaccctcaaccacatagaaacgacttgga
resulting in melting points of 61, and 52 °C for the
wild-type and the mutated allele, respectively.
Statistics
Binary logistic regression analyses, Mann–Whitney U-test,
Kruskal-Wallis, and T-test have been performed employ-
ing the IBM SPSS Statistics software package (version
20.0, IBM, Munich, Germany).
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Results
Association of common risk factors with age related
diseases
First we analyzed whether common risk factors such as
age, BMI, micro-inflammation (presented as IL-6 levels),
smoking, and hypertension are associated with aging-
related diseases in our cohort of elderly Caucasians by
comparison of healthy subjects without any aging-related
disease (n = 517), and subjects suffering from one or more
aging-related diseases (n = 1027), e.g. CVD (n = 496), can-
cer (n = 93), lung disease (n = 254), DMT 2 (n = 122), and
cognitive impairment (n = 406). Baseline characteristics of
the cohort are shown in Table 1. As expected, increased
age and BMI were strongly associated with the occurrence
of aging-related diseases (P < 0.001 for both). Also
inflamm-aging, determined by baseline IL-6 levels with
levels ≤1 ng/L serving as reference and 1.1–2.0 ng/L as
intermediate or >2 ng/L as high levels, could be shown to
be a strong risk factor (P = 0.016 and P < 0.001, respect-
ively). Hypertension, interestingly, failed to be a significant
risk factor in our cohort. Surprisingly, current smoking
revealed a significant “protective” effect (P = 0.003, OR:
0.586), whereas past smoking showed no association
(Table 2). However, further analysis of the distribution of
age and BMI in nonsmokers, past smokers, and current
smokers revealed current smokers to be significantly
younger and having a significantly lower BMI, which
might account for the “protective” effect of current smok-
ing (data not shown). Indeed, performing a multivariate
analysis with inflamm-aging, age, BMI and smoking as risk
factors revealed that micro-inflammation - presented as
intermediate or high IL-6 levels -, age and BMI remained
significant independent risk factors in our elderly cohort,
with P-values of 0.034, 0.001, 0.001, and 0.008, respect-
ively. Past smoking and current smoking in a multivariate
analysis failed to be significantly associated with aging-
related diseases (Table 3).
The TLR-6 variant 249S/S is significantly associated with
protection from aging-related diseases in non-smoking
subjects
Having shown that common risk factors (with the excep-
tion of smoking) exhibited the expected association with
aging-related diseases in our cohort, we next analyzed
whether the TLR-6 P249S variation is also associated
with such diseases. Analyzing the whole cohort by logis-
tic regression, using the wild-type genotype as reference
we failed to find any significant association. Correction
for age, BMI and inflamm-aging was done by adding
these factors as co-factors in the regression analysis
(Table 4). Since in this population smokers are signifi-
cantly younger and exhibit a significantly lower BMI the
pattern of association of smoking with diseases could
not be analyzed in detail, and in order to avoid further
statistical problems, only non-smokers were selected for




Mean age (SD) 76.76 (6.44)
Males/females 811/733
Mean BMI (SD) 28.46 (4.87)
Smoking: never/past/current (%) 849 (55.0)/534 (34.6)/152 (9.8)
Hypertension yes/no (%) 1167/372 (75.6/24.1)
Baseline IL-6 (ng/L) 3.21 (2.98)
Disease-free 517 (33.5)
CVD (%) 496 (32.1)
Cancer (%) 93 (6.0)
Lung disease (%) 254 (16.5)
DMT 2 (%) 122 (7.9)
Cognitive impairment (%) 406 (26.3)
TLR-6 PP/PS/SS (%) 615 (39.8)/718 (46.5)/211 (13.7)
Table 2 Association of common risk factors with aging-related
diseases in the PolSenior group. Univariate analysis of common
risk factors and aging related diseases
Risk factor P-value Mean (SD)
Age <0.001 75.7 (6.6)/77.3 (6.3)
BMI <0.001 27.9(4.8)/28.6 (4.9)
P-value OR (95 % CI)
IL-6 Intermediate 0.016 1.578 (1.088–2.289)
High <0.001 2.108 (1.472–3.020)
Smoking Past 0.619 1.061 (0.841–1.338)
Current 0.003 0.586 (0.413–0.831)
Hypertension 0.175 1.184 (0.928–1.512)
Age was analyzed by T-test and BMI was analyzed by Mann–Whitney U test.
Micro-inflammation (IL-6), smoking and hypertension were analyzed by logistic
regression with IL-6 levels ≤1 ng/L as reference and 1.1–2.0 ng/L (intermediate)
and >2 ng/L (high) as predictors, as well as no smoking or no hypertension
as reference
Table 3 Association of common risk factors with aging-related
diseases in the PolSenior group. Multivariate analysis of common
risk factors and aging-related diseases
Risk factor P-value OR (95 % CI)
Age 0.001 1.033 (1.014–1.052)
BMI 0.008 1.033 (1.009–1.058)
IL-6 Intermediate 0.034 1.507 (1.031–2.202)
High 0.001 1.863 (1.286–2.700)
Smoking Past 0.310 1.134 (0.890–1.446)
Current 0.052 0.683 (0.465–1.003)
Analysis was done by logistic regression with IL-6 levels ≤1 ng/L as reference
and 1.1–2.0 ng/L (intermediate) and >2 ng/L (high) as predictors for inflamm-aging,
and no smoking as reference
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association studies of TLR-6 polymorphism with aging-
related diseases.
Comparing non-smoking healthy subjects (n = 278)
with non-smoking diseased subjects (n = 571) we found
a significant protective association of the TLR-6 P/S
and TLR-6 S/S variants with aging-related diseases in
general, P = 0.024, OR: 0.682 (95 % CI: 0.489–0.951)
and P = 0.018, OR: 0.566 (95 % CI: 0.353–0.909), respect-
ively. The protective effect for mutated allele carriers was
still in effect when heterozygous and homozygous geno-
types were combined, P = 0.008, OR: 0.654 (95 % CI:
0.477–0.897) (Table 4), which is compatible with the dom-
inant model. No significant effects were found in formerly
or currently smoking subjects, which, as stated above, may
be due to the different age-distribution of these groups
(data not shown). As shown in Table 5, a subgroup ana-
lysis of individual diseases revealed a significant protective
effect of the TLR-6 S/S variant regarding CVD (n = 255),
P = 0.018, OR: 0.483 (95 % CI: 0.265–0.882). Correction
for age, BMI and inflamm-aging was done by adding
these factors as co-factors in the regression analysis.
Interestingly, the heterozygous P/S variant as well as
the combined heterozygous and homozygous genotypes
exhibited a significant protection regarding DMT 2
(n = 79), P = 0.007 OR: 0.443 (95 % CI: 0.244–0.804)
and P = 0.010 OR: 0.486 (95 % CI: 0.281–0.839), re-
spectively. For cancer (n = 42), lung disease (n = 116), and
cognitive impairment (n = 250), no significant associations
were found. Analysis of combined aging-related diseases
with exclusion of CVD (n = 309) revealed significant
protection for the TLR-6 P/S variant, P = 0.016 OR. 0.628
(95 % CI: 0.431–0.915) and the combined heterozygous
and homozygous genotypes, P = 0.012, OR: 0.635 (95 %
CI: 0.445–0.906) indicating a protective effect independent
of the protection against CVD.
No association of TLR-6 6 P249S variation with baseline
IL-6 levels
Since we have speculated previously that a beneficial
effect of TLR SNPs may rely on a decreased process
of inflamm-aging due to a reduced sensitivity of the
innate immune system, we analyzed whether the TLR-
6 P249S variant was associated with baseline levels of
IL-6. To exclude current infections that could affect
the level of IL-6, we excluded subjects with a white
blood cell count above 10.000/μl. As shown in Table 6,
baseline IL-6 levels are significantly higher in subjects
suffering from one or more aging-related diseases in
comparison to healthy subjects: 3.33 ng/L vs. 2.75 ng/
L, P >0.000. Although there is a trend for decreased
IL-6 baseline levels in S allele carriers, P/P: 3.23 ng/
L, P/S: 3.08 ng/L and S/S: 3.05 ng/L, this association
is not significant, P = 0.850.
Table 4 TLR-6 P249S is associated with healthy aging in
non-smokers





P/S 0.281 0.876 (0.689–1.114)
S/S 0.273 0.825 (0.585–1.163)





P/S 0.024 0.682 (0.489–0.951)
S/S 0.018 0.566 (0.353–0.909)
P/S + S/S 0.008 0.654 (0.477–0.897)
P-values and OR were determined by logistic regression using the wild type
genotype as reference, and micro-inflammation (IL-6 level), age and BMI
as co-factors. Subjects with a white blood cell count above 10.000/μl
were excluded
Table 5 TLR-6 P249S is associated with CVD and DMT 2 in
non-smokers
Disease Variant P-value OR (95 % CI)
All subjects
CVD P/P - -
P/S 0.188 0.770 (0.522–1.136)
S/S 0.018 0.483 (0.265–0.882)
P/S + S/S 0.061 0.702 (0.484–1.017)
Cancer P/P - -
P/S 0.416 0.745 (0.367–1.513)
S/S 0.353 0.602 (0.207–1.756)
P/S + S/S 0.318 0.710 (0.363–1.390)
Lung disease P/P - -
P/S 0.216 0.732 (0.446–1.201)
S/S 0.509 0.793 (0.399–1.577)
P/S + S/S 0.219 0.746 (0.467–1.191)
DMT 2 P/P - -
P/S 0.007 0.443 (0.244–0.804)
S/S 0.230 0.617 (0.281–1.356)
P/S + S/S 0.010 0.486 (0.281–0.839)
Cognitive impairment P/P - -
P/S 0.284 0.794 (0.522–1.210)
S/S 0.345 0.751 (0.415–1.360)




P/S 0.016 0.628 (0.431–0.915)
S/S 0.116 0.656 (0.388–1.109)
P/S + S/S 0.012 0.635 (0.445–0.906)
P-values and OR were determined by logistic regression using the wild type
genotype as reference, and micro-inflammation (IL-6 level), age and BMI as
co-factors. Subjects with a white blood cell count above 10.000/μl were excluded
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Discussion
We have recently shown that TLR-6 P249S is associated
with coronary artery disease, one of the most important
aging-related diseases, and have speculated that this gen-
etic variation may be also associated with healthy aging
in general by decreasing the process of inflamm-aging
due to decreased sensitivity of the innate immune re-
sponse [14, 19]. Healthy, or successful aging is affected
by a variety of factors including environmental factors,
life style, micro-inflammation, and genetic factors that
determine the occurrence, onset and course of aging-
related diseases. Since most age-related diseases are
associated with chronic inflammation [21], a sensitive
immune system may be an example of antagonistic
pleiotropy with beneficial effects at early age but adverse
effects in later life since evolution optimizes for fitness,
not for longevity [22]. By analyzing a middle-aged
population-based cohort, exhibiting the typical distribu-
tion of aging-related diseases, we here confirmed our
previous finding of TLR-6 P249S being associated with
CVD and showed that this SNP is associated with
healthy aging in non-smoking subjects of the PolSenior
cohort. This positive association with healthy aging
remains significant after exclusion of subjects suffering
from CVD indicating a more general effect, not only
restricted to CVD. Furthermore we present first evi-
dence of this SNP to be also involved in DMT-2 and the
process of inflamm-aging in non-smoking subjects.
We have currently no conclusive explanation why this
effect could not be shown in smoking subjects. Although
our study does not show smoking to be one of the stron-
gest risk factors for aging-related diseases in individuals
65 years old and older, the effect of TLR-6 variants on
healthy aging may nevertheless be masked by smoking.
Such modifying effect of smoking has recently been re-
ported for several genetic associations in age-related
macular degeneration which are largely restricted to
non-smokers [23]. One possible explanation could be
that in our cohort smoking is associated with both,
lower ager and lower BMI which in turn are associated
with the absence of aging-related diseases. The associ-
ation of TLR-6 P249S with DMT 2 has not been shown
before. However, since the number of non-smoking sub-
jects with DMT 2 was rather low in our cohort (n = 79),
and TLR-6 has not been found by GWAs for DMT 2,
these findings have to be confirmed in larger studies [24].
Analyzing the whole cohort for common risk factors
by multivariate regression analysis showed, as expected,
increased age, BMI, and inflamm-aging to be strongly
associated with the occurrence of aging-related diseases.
Since we have previously speculated that less functional
TLR variants decreasing the sensitivity of the innate im-
mune system may dampen the process of inflamm-
aging, we analyzed the association of TLR-6 P249S with
baseline IL-6 levels. Although the S allele at position 249
of TLR-6 has been shown to decrease TLR-6 signaling
[25], we could not find a significant effect on inflamm-
aging. However, we could show a trend towards de-
creased IL-6 levels in S allele carriers. The failure of
finding significant changes may potentially be explained
by the fact that other pro-inflammatory cytokines such
as TNF-α and IL-1β, the serum-levels of which were not
available to us, may be more involved in the process of
inflamm-aging as compared to IL-6. Recent data show
that inflamm-aging is not simply the chronic increase of
pro-inflammatory markers such as IL-6 and CRP.
Inflamm-aging seem to be much more complex and is
characterized by the simultaneous change in both pro-
and anti- inflammatory markers [26]. Furthermore, re-
peated measurements of IL-6 levels, which were not
available to us in this cohort are known to be more ac-
curate in determining inflamm-aging [2]. Finally, the
SNPs investigated by us may lead to changes in cyto-
kines in certain tissues, which cannot be monitored by
measuring serum levels.
On the other hand, comparing healthy subjects with
diseased subjects, a strong correlation of increased IL-6
baseline levels and aging-related diseases was shown.
This may be evidence for the fact that inflamm-aging is
driven mainly by a dysregulated T lymphocyte subpopu-
lation [2] and chronic stimulation of the innate immune
system via TLRs does not play the dominant role.
Since the limitation of our study is relatively small sam-
ple number, especially in disease subgroups, our results
require further investigation by independent studies.
Conclusion
In conclusion we confirm here our previous results of
less functional TLR-6 variant 249S to protect from
CVD. In addition we show here that this variant pro-
tects also from DMT-2 and is in general associated
with healthy aging in the PolSenior cohort. Further-
more, we could show a trend for a decreased process
Table 6 TLR-6 P249S is not associated with baseline levels of IL-6
IL-6 (ng/L, mean, SD) P-value
Disease free 2.75 (2.60) <0.001
Aging related diseases 3.33 (3.01)
TLR-6 genotype
P/P 3.23 (3.05) 0.850
P/S 3.08 (2.73)
S/S 3.05 (2.93)
P-values were determined by Mann–Whitney U test or Kruskal-Wallis test,
subjects with white blood cells above 10.000/μl were excluded
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of inflamm-aging by the TLR-6 249S allele as measured
by IL-6 levels. However, the effect of TLR variants on
the process of inflamm-aging needs to be confirmed by
further studies.
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